2023
Sicking M.,Falke I., Löblein M. T., Eich H. T., Götte M., Greve B., Troschel F. M., The Musashi RNA-binding proteins in female cancers: insights on molecular mechanisms and therapeutic relevance. Biomark Res. doi: 10.1186/s40364-023-00516-2
Haiduk T. S.*, Sicking M.*, Brücksken K. A., Espinoza-Sánchez N.A., Eder K. M., Kemper B., Eich H. T., Götte M., Greve B., Troschel F. M. Dysregulated stem cell markers Musashi-1 and Musashi-2 are associated with therapy resistance in inflammatory breast cancer. Arch Med Res. doi: 10.1016/j.arcmed.2023.102855
Frey B., Borgmann K., Jost R., Greve B., Oertel M., Micke O., Eckert F., DNA as the main target in radiotherapy- a historical overview from first isolation to anti-tumor immune response. Strahlenther Onkol. doi: 10.1007/s00066-023-02122-5
Wischmann FJ, Troschel FM, Frankenberg M, Kemper B, Vijaya Kumar A, Sicking M, Ibrahim SA, Kiesel L, Götte M, Eich HT, Greve B. Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation. J Cancer Res Clin Oncol. doi: 10.1007/s00432-023-04750-x
Hassan N, Bückreiß N, Efing J, Schulz-Fincke M, König P, Greve B, Bendas G, Götte M. The Heparan Sulfate Proteoglycan Syndecan-1 Triggers Breast Cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor. Cells. doi: 10.3390/cells12060910
Espinoza-Sánchez NA, Troschel F, Greve B, Götte M. Proteoglycan Expression Studied by MicroRNAs. Methods Mol Biol. doi: 10.1007/978-1-0716-2946-8_20
2022
Oertel M, Borrmann K, Baehr A, Eich HT, Greve B. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy. Radiat Oncol. doi: 10.1186/s13014-022-02167-3
Krautschneider SL, Troschel FM, Vadillo E, Eich HT, Götte M, Espinoza-Sánchez NA, Greve B. Enzymatic Digestion of Cell-surface Heparan Sulfate Alters the Radiation Response in Triple-negative Breast Cancer Cells. Arch Med Res. doi: 10.1016/j.arcmed.2022.11.004
Hillemeyer L, Espinoza-Sanchez NA, Greve B, Hassan N, Chelariu-Raicu A, Kiesel L, Götte M. The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis. Int J Mol Sci. doi: 10.3390/ijms23105793
Falke I, Troschel FM, Palenta H, Löblein MT, Brüggemann K, Borrmann K, Eich HT, Götte M, Greve B. Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation. Stem Cell Res Ther. doi: 10.1186/s13287-022-02891-3
D'Arcy C, Zimmermann CC, Espinoza-Sanchez NA, Greve B, Schmidt A, Kiesel L, von Wahlde MK, Götte M. The heparan sulphate proteoglycan Syndecan-1 (CD138) regulates tumour progression in a 3D model of ductal carcinoma in situ of the breast. IUBMB Life. doi: 10.1002/iub.2623
Madanes D, Meresman G, Valla SA, Hassan N, Kiesel L, Greve B, Barañao RI, Götte M, Ricci AG. Resveratrol impairs cellular mechanisms associated with the pathogenesis of endometriosis. Reprod Biomed Online. doi: 10.1016/j.rbmo.2022.02.008
Strauß T, Greve B, Gabriel M, Achmad N, Schwan D, Espinoza-Sanchez NA, Laganà AS, Kiesel L, Poutanen M, Götte M, Schäfer SD. Impact of Musashi-1 and Musashi-2 Double Knockdown on Notch Signaling and the Pathogenesis of Endometriosis. Int J Mol Sci. doi: 10.3390/ijms23052851
Steike DR, Hessler M, Korsching E, Lehmann F, Schmidt C, Ertmer C, Schnekenburger J, Eich HT, Kemper B, Greve B. Digital Holographic Microscopy for Label-Free Detection of Leukocyte Alternations Associated with Perioperative Inflammation after Cardiac Surgery. Cells. doi: 10.3390/cells11040755
Hilgers K, Ibrahim SA, Kiesel L, Greve B, Espinoza-Sánchez NA, Götte M. Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells. Front Oncol. doi: 10.3389/fonc.2022.803899
Kahl I, Mense J, Finke C, Boller AL, Lorber C, Győrffy B, Greve B, Götte M, Espinoza-Sánchez NA. The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients. J Cell Biochem. doi: 10.1002/jcb.30205
Kyriakopoulou K, Kefali E, Piperigkou Z, Riethmüller C, Greve B, Franchi M, Götte M, Karamanos NK. EGFR is a pivotal player of the E2/ERβ – mediated functional properties, aggressiveness, and stemness in triple-negative breast cancer cells. FEBS J. doi: 10.1111/febs.16240
2021
Cocola C, Magnaghi V, Abeni E, Pelucchi P, Martino V, Vilardo L, Piscitelli E, Consiglio A, Grillo G, Mosca E, Gualtierotti R, Mazzaccaro D, La Sala G, Di Pietro C, Palizban M, Liuni S, DePedro G, Morara S, Nano G, Kehler J, Greve B, Noghero A, Marazziti D, Bussolino F, Bellipanni G, D'Agnano I, Götte M, Zucchi I, Reinbold R. Transmembrane Protein TMEM230, a Target of Glioblastoma Therapy. Front Cell Neurosci. doi: 10.3389/fncel.2021.703431
Löblein MT, Falke I, Eich HT, Greve B, Götte M, Troschel FM. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells. Int J Mol. doi: 10.3390/ijms222111502
Troschel FM, Palenta H, Borrmann K, Heshe K, Hua SH, Yip GW, Kiesel L, Eich HT, Götte M, Greve B. Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1. J Cancer Res Clin Oncol. doi: 10.1007/s00432-021-03743-y
Troschel FM, Linsenmaier M, Borrmann K, Eich HT, Götte M, Greve B. Heparanase Expression Is Associated With Cancer Stem Cell Features and Radioresistance in Hodgkin's Lymphoma Cells. Anticancer Res. doi: 10.21873/anticanres.15117
Onyeisi JOS, Greve B, Espinoza-Sánchez NA, Kiesel L, Lopes CC, Götte M. microRNA-140-3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan-4. J Cell Biochem. doi: 10.1002/jcb.30071
Valla S, Hassan N, Vitale DL, Madanes D, Spinelli FM, Teixeira FCOB, Greve B, Espinoza-Sánchez NA, Cristina C, Alaniz L, Götte M. Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells. Int J Mol Sci. doi: 10.3390/ijms22115874
Nassar E, Hassan N, El-Ghonaimy EA, Hassan H, Abdullah MS, Rottke TV, Kiesel L, Greve B, Ibrahim SA, Götte M. Syndecan-1 Promotes Angiogenesis in Triple- Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes. Cancers (Basel). doi: 10.3390/cancers13102318
Ahmed SH, Espinoza-Sánchez NA, El-Damen A, Fahim SA, Badawy MA, Greve B, El-Shinawi M, Götte M, Ibrahim SA. Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next generation plasma biopsy-based diagnostic biomarkers for inflammatory breast cancer. PLoS One. doi: 10.1371/journal.pone.0250642
Mc Cormack B, Maenhoudt N, Fincke V, Stejskalova A, Greve B, Kiesel L, Meresman GF, Vankelecom H, Götte M, Barañao RI. The ellagic acid metabolites urolithin A and B differentially affect growth, adhesion, motility, and invasion of endometriotic cells in vitro. Hum Reprod. doi: 10.1093/humrep/deab053
Stejskalová A, Fincke V, Nowak M, Schmidt Y, Borrmann K, von Wahlde MK, Schäfer SD, Kiesel L, Greve B, Götte M. Collagen I triggers directional migration, invasion and matrix remodeling of stroma cells in a 3D spheroid model of endometriosis. Sci Rep. doi: 10.1038/s41598-021-83645-8
Kuehn J, Espinoza-Sanchez NA, Teixeira FCOB, Pavão MSG, Kiesel L, Győrffy B, Greve B, Götte M. Prognostic significance of hedgehog signaling network-related gene expression in breast cancer patients. J Cell Biochem. doi: 10.1002/jcb.29886
Hassan N, Greve B, Espinoza-Sánchez NA, Götte M. Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer. Cell Signal. doi: 10.1016/j.cellsig.2020.109822
2020
Manou D, Bouris P, Kletsas D, Götte M, Greve B, Moustakas A, Karamanos NK, Theocharis AD. Serglycin activates pro-tumorigenic signaling and controls glioblastoma cell stemness, differentiation and invasive potential. Matrix Biol Plus. doi: 10.1016/j.mbplus.2020.100033
El-Nadi M, Hassan H, Saleh ME, Nassar E, Ismail YM, Amer M, Greve B, Götte M, El-Shinawi M, Ibrahim SA. Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas. Matrix Biol Plus. doi: 10.1016/j.mbplus.2020.100030
Teixeira FCOB, Vijaya Kumar A, Kumar Katakam S, Cocola C, Pelucchi P, Graf M, Kiesel L, Reinbold R, Pavão MSG, Greve B, Götte M. The Heparan Sulfate Sulfotransferases HS2ST1 and HS3ST2 Are Novel Regulators of Breast Cancer Stem-Cell Properties. Front Cell Dev Biol. doi: 10.3389/fcell.2020.559554
Fahim SA, Abdullah MS, Espinoza-Sánchez NA, Hassan H, Ibrahim AM, Ahmed SH, Shakir G, Badawy MA, Zakhary NI, Greve B, El-Shinawi M, Götte M, Ibrahim SA. Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value. Biomolecules. doi: 10.3390/biom10071059
Vijaya Kumar A, Brézillon S, Untereiner V, Sockalingum GD, Kumar Katakam S, Mohamed HT, Kemper B, Greve B, Mohr B, Ibrahim SA, Goycoolea FM, Kiesel L, Pavão MSG, Motta JM, Götte M. HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior. Cancer Sci. doi: 10.1111/cas.14539
Katakam SK, Pelucchi P, Cocola C, Reinbold R, Vlodavsky I, Greve B, Götte M. Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells. Front Oncol. doi: 10.3389/fonc.2020.00774
Katakam SK, Tria V, Sim WC, Yip GW, Molgora S, Karnavas T, Elghonaimy EA, Pelucchi P, Piscitelli E, Ibrahim SA, Zucchi I, Reinbold R, Greve B, Götte M. The heparan sulfate proteoglycan syndecan-1 regulates colon cancer stem cell function via a focal adhesion kinase-Wnt signaling axis. FEBS J. doi: 10.1111/febs.15356
Troschel FM, Minte A, Ismail YM, Kamal A, Abdullah MS, Ahmed SH, Deffner M, Kemper B, Kiesel L, Eich HT, Ibrahim SA, Götte M, Greve B. Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer.Int J Mol Sci. doi: 10.3390/ijms21062169
Brand C, Greve B, Bölling T, Eich HT, Willich N, Harrach S, Hintelmann H, Lenz G, Mesters RM, Kessler T, Schliemann C, Berdel WE, Schwöppe C. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma. PLoS One. doi: 10.1371/journal.pone.0229271
Elsayad K, Kroeger K, Greve B, Moustakis C, Assaf C, Stadler R, Lenz G, Weishaupt C, Eich HT. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome. Strahlenther Onkol. doi: 10.1007/s00066-019-01517-7
2019
Ramirez Williams L, Brüggemann K, Hubert M, Achmad N, Kiesel L, Schäfer SD, Greve B, Götte M. γ-Secretase inhibition affects viability, apoptosis, and the stem cell phenotype of endometriotic cells. Acta Obstet Gynecol Scand. doi: 10.1111/aogs.13707
Weidner J, Hünger F, Odaibo G, Olaleye D, Reichelt D, Greve B, Cassens U. Storage and Transportation of "HIV" RNA in Plasma Samples up to 45°C in a Lyophilized Stabilizer. Clin Lab. doi: 10.7754/Clin.Lab.2019.190126
Vitale D, Kumar Katakam S, Greve B, Jang B, Oh ES, Alaniz L, Götte M. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance.FEBS J. doi: 10.1111/febs.14967
Min J, Yao B, Trendafilova V, Ketelhut S, Kastl L, Greve B, Kemper B. Quantitative phase imaging of cells in a flow cytometry arrangement utilizing Michelson interferometer-based off-axis digital holographic microscopy. J Biophotonics. doi: 10.1002/jbio.201900085
Gadalla R, Hassan H, Ibrahim SA, Abdullah MS, Gaballah A, Greve B, El-Deeb S, El-Shinawi M, Mohamed MM. Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis. Breast Cancer Res Treat. doi: 10.1007/s10549-019-05129-8
Weitere Publikationen
